Jung W.,University of Cincinnati |
Han J.,Siloam Biosciences, Inc. |
Choi J.-W.,Louisiana State University |
Ahn C.H.,University of Cincinnati
Microelectronic Engineering | Year: 2014
Point-of-care testing (POCT) is necessary to provide a rapid diagnostic result for a prompt on-site diagnosis and treatment. A quick analysis time and high sensitivity, with a sample-to-answer format, are the most important features for current POCT diagnostic systems. Microfluidic lab-on-a-chip technologies have been considered as one of the promising solutions that can meet the requirement of the POCT since they can miniaturize and integrate most of the functional modules used in central laboratories into a small chip. This review covers recent advances in POCT technologies with an emphasis on demonstrated and commercially available POCT diagnostic systems with laboratory quality using microfluidic lab-on-a-chip technologies. As working principles and required functional modules depend on target analytes, we categorize the applications of the POCT diagnostic systems according to the analyte types such as proteins, cells, nucleic acids, and metabolites. In each analyte category, detection methods, configuration of POCT lab-on-a-chip modules, and advantages and disadvantages of POCT systems are reviewed and discussed along with future prospects. © 2014 Elsevier B.V. All rights reserved.
Lee Y.-G.,Sungkyunkwan University |
Han J.,Siloam Biosciences, Inc. |
Kwon S.,Mine Reclamation Corporation |
Kang S.,Kyung Hee University |
Jang A.,Sungkyunkwan University
Chemosphere | Year: 2016
Atomic absorption spectrometry and inductively coupled plasma-mass spectrometry are widely used for determination of heavy metals due to their low detection limits. However, they are not applicable to on-site measurements of heavy metals as bulky equipment, and highly skilled laboratory staffs are needed as well. In this study, a novel analytical method using a rotary disc voltammetric (RDV) sensor has been successfully designed, fabricated and characterized for semi-continuous and on-site measurements of trace levels of Pb(II) in non-deoxygenating solutions. The square wave anodic stripping voltammetry was used to improve the sensitivity of the Pb(II) detection level with less than 10nM (2μgL-1). The RDV sensor has 24-sensing holes to measure concentrations of Pb(II) semi-continuously at sampling sites. Each sensing hole consists of a silver working electrode, an integrated silver counter, and a quasi-reference electrode, which requires only a small amount of samples (<30μL) for measurement of Pb(II) without disturbing and/or clogging the sensing environment. In addition, the RDV sensor showed a correlation coefficient of 0.998 for the Pb(II) concentration range of 10nM-10μM at the deposition time of 180s and its low detection limit was 6.19nM (1.3μgL-1). These results indicated that the advanced monitoring technique using a RDV sensor might provide environmental engineers with a reliable way for semi-continuous and on-site measurements of Pb(II). © 2015 Elsevier Ltd.
Kai J.,Siloam Biosciences, Inc. |
Puntambekar A.,Siloam Biosciences, Inc. |
Santiago N.,Siloam Biosciences, Inc. |
Lee S.H.,Siloam Biosciences, Inc. |
And 5 more authors.
Lab on a Chip - Miniaturisation for Chemistry and Biology | Year: 2012
In this work we introduce a novel microfluidic enzyme linked immunoassays (ELISA) microplate as the next generation assay platform for unparalleled assay performances. A combination of microfluidic technology with standard SBS-configured 96-well microplate architecture, in the form of microfluidic microplate technology, allows for the improvement of ELISA workflows, conservation of samples and reagents, improved reaction kinetics, and the ability to improve the sensitivity of the assay by multiple analyte loading. This paper presents the design and characterization of the microfluidic microplate, and its application in ELISA. © 2012 The Royal Society of Chemistry.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 997.25K | Year: 2011
Recent clinical research has established that this ratio is indicative of the activity of the CYP2A6 enzyme that metabolises nicotine. Nicotine is metabolized to COT and then to 3HC. People with high activity of this enzyme, clear nicotine faster and henceneed more nicotine to maintain the addiction. To-date the 3HC/COT ratio could only be determined by specialized measurement techniques such as Liquid-Chromatography/Mass Spectrometry. Although accurate, these tests are expensive and take 2-5 days to deliver results. Smoking is the leading cause of cancer related deaths, and is attributable cause for almost 400,000 deaths per year in the US> The POCT for nicotine metabolites can help in increasing smoking cessation rates and directly contribute to reduced mortality/healthcare burden.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 997.44K | Year: 2014
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 198.57K | Year: 2012
The goal of this SBIR project is to develop a low lost, ultrasensitive immunodiagnostic system for measuring multiple cancer biomarkers rapidly with small amount of samples. This system can be used by physicians to improve cancer early detection, diagnosis, prognosis and treatment monitoring. Cancer biomarkers have been widely used for cancer early detection and diagnosis. Assay with multiple cancer biomarkers can significantly increase the sensitivity and specificity. Current detection platforms are limited in multiple ways to effectively address those needs. Instruments that are fast, can work with low sample volumes are typically expensive and have limited sensitivity. Ultra-high sensitivity platforms are also expensive and typically require complex sample prep steps and large sample volumes. Siloam has developed a novel Optimiser microfluidic assay platform, for meauring multiple analytes with 20x sensitivity, 20x less sample and reagent consumption and total assay times less than 20 minutes. Use ofthis technology allows for limited automation system to operate as a fully automated immunodiagnostic analyzer. Cancer is the leading cause of deaths worldwide. 571,950 deaths from cancer are projected to occur in US in the 2011. The Immunodiagnostic system can help in early cancer detection and diagnosis and directly contribute to reduced mortality/healthcare burden.
Siloam Biosciences, Inc. | Date: 2013-07-16
A point of care testing assay system for determining the presence and/or amount of an analyte of interest in a sample, and methods for using such assay system, are disclosed. The system comprises a microfluidic means capable of performing testing with low sample volume in a sample matrix, and having high sensitivity and substantially a 5-log wide dynamic range and capable of performing an assay in approximately fifteen minutes, and in which the microfluidic means comprises a microfluidic testing cartridge with associated electronics, a precision pipettor, a high sensitivity detection module, a motion stage, and an on-board electronics display means that can be read by a user as an indication of the presence and/or amount of the analyte in the sample.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 150.00K | Year: 2010
The goal of this fast-track SBIR project is to develop the first ever, point-if-care test (POCT) to determine the ratio of nicotine metabolites
Siloam Biosciences, Inc. | Date: 2014-01-16
Siloam Biosciences, Inc. | Date: 2013-03-09
Medical diagnostic reagents and assays for testing of body fluids.